Recently, LW402 was approved to conduct clinical studies in vitiligo. LW402 is a next-generation highly selective JAK1 inhibitor independently developed by LWBP. The safety and efficacy of LW402 have been verified in clinical studies of rheumatoid arthritis (RA), atopic dermatitis (AD), and other indications, and its efficacy and safety are significantly better than those of the marketed competitor products.
Vitiligo is a chronic autoimmune disease, with a global prevalence of about 2%. Clinically, it manifests as localized or generalized white patches on the skin caused by melanin deficiency. Clinically, vitiligo is classified as segmental (SV), non-segmental (NSV), mixed and undetermined. According to the research report of Topsperity Securities, the global prevalence of vitiligo is about 0.5%-2%, and the number of vitiligo patients in China is about 22 million in 2021, with the prevalence rate showing a gradual upward trend in recent years.
Currently, there is a lack of effective symptomatic drug treatment for vitiligo in the market, and there is no oral targeted drug on the market globally, so there is a huge gap in the market. In preclinical studies, LW402 successfully promoted repigmentation of depigmented areas in vitiligo model animals, a breakthrough that is expected to fill the $10 billion vitiligo drug market.
About LWBP
长Founded in 2012, LWBP is an innovative drug R&D company led by world-renowned chemical drug experts. The company is committed to independently developing world-leading innovative drugs with global intellectual property rights to meet unmet clinical needs. Focusing on the development and industrialization of innovative drugs in the fields of antiviral, tumour immunity and autoimmune diseases, the company has carried out a number of self-developed small molecule drugs (FIC, first in class), and a number of them have entered the clinical trial stage. The core products have reached the international leading level in terms of clinical evaluation indexes, and are expected to become a major breakthrough in the relevant fields (New Class, First-in-Class).
About LW402
LW402 is a next-generation oral JAK1 inhibitor independently developed by LWBP for the treatment of autoimmune diseases such as atopic dermatitis, rheumatoid arthritis, vitiligo and so on. LW402 is a more efficient and safer JAK1 selective inhibitor, which can effectively control the progression of autoimmune diseases by inhibiting cytokine signals through blocking the JAK-STAT signalling pathway, and is expected to become a new and important therapy for the treatment of autoimmune diseases. LW402 has the potential to become the best choice for the treatment of rheumatoid arthritis, atopic dermatitis, vitiligo, etc., with a promising prospect for commercialisation.
